Literature DB >> 20628172

A modeling and simulation framework to support early clinical drug development decisions in oncology.

Rene Bruno1, Jian-Feng Lu, Yu-Nien Sun, Laurent Claret.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20628172     DOI： 10.1177/0091270010376970

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  10 in total

Review 1.  Covariate pharmacokinetic model building in oncology and its potential clinical relevance.

Authors:  Markus Joerger
Journal:  AAPS J       Date:  2012-01-25       Impact factor: 4.009

2.  Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer.

Authors:  Xu Steven Xu; Charles J Ryan; Kim Stuyckens; Matthew R Smith; Fred Saad; Thomas W Griffin; Youn C Park; Margaret K Yu; Peter De Porre; An Vermeulen; Italo Poggesi; Partha Nandy
Journal:  Clin Pharmacokinet       Date:  2017-01       Impact factor: 6.447

3.  Intracellular-signaling tumor-regression modeling of the pro-apoptotic receptor agonists dulanermin and conatumumab.

Authors:  Brittany P Kay; Cheng-Pang Hsu; Jian-Feng Lu; Yu-Nien Sun; Shuang Bai; Yan Xin; David Z D'Argenio
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-08-30       Impact factor: 2.745

4.  Predicting Overall Survival and Progression-Free Survival Using Tumor Dynamics in Advanced Breast Cancer Patients.

Authors:  Hyeong-Seok Lim; Wan Sun; Kourosh Parivar; Diane Wang
Journal:  AAPS J       Date:  2019-01-30       Impact factor: 4.009

5.  Modeling NSCLC progression: recent advances and opportunities available.

Authors:  Ahmed Abbas Suleiman; Lucia Nogova; Uwe Fuhr
Journal:  AAPS J       Date:  2013-02-13       Impact factor: 4.009

6.  Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin.

Authors:  J G C van Hasselt; A Gupta; Z Hussein; J H Beijnen; J H M Schellens; A D R Huitema
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-06-30

7.  Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression.

Authors:  M Zhu; R Tang; S Doshi; K S Oliner; S Dubey; Y Jiang; R C Donehower; T Iveson; E Y Loh; Y Zhang
Journal:  Br J Cancer       Date:  2015-01-13       Impact factor: 7.640

8.  PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST.

Authors:  E K Hansson; M A Amantea; P Westwood; P A Milligan; B E Houk; J French; M O Karlsson; L E Friberg
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-11-20

Review 9.  Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities.

Authors:  Nidal Al-Huniti; Yan Feng; Jingyu Jerry Yu; Zheng Lu; Mario Nagase; Diansong Zhou; Jennifer Sheng
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-07-22

10.  Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling.

Authors:  C H Li; R R Bies; Y Wang; M R Sharma; S Karovic; L Werk; M J Edelman; A A Miller; E E Vokes; A Oto; M J Ratain; L H Schwartz; M L Maitland
Journal:  Clin Transl Sci       Date:  2016-01-21       Impact factor: 4.689
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.